Personal Finance

Here's Why Celldex Therapeutics Sank on Friday

Frustrated stock trader in front of monitors.

What happened

Shares of Celldex Therapeutics Inc. (NASDAQ: CLDX) , a clinical-stage biopharmaceutical company developing novel new cancer therapies, slipped 13% on Friday. There wasn't any news specific to the company today -- it just fell along with the rest of the industry.

So what

Celldex Therapeutics hasn't had much to say to investors since presenting pre-clinical data in November. The stock slid along with the Nasdaq Biotechnology Index, which dropped 11% this week.

Frustrated stock trader in front of monitors.

Image source: Getty Images.

If we've learned anything this year, it's that combining immunotherapies doesn't work nearly as often as was expected a couple years ago. Investors losing faith in the combination approach is a problem for Celldex because none of its experimental therapies seem to do much on their own.

Celldex reported results from the first four ascending cohorts in a dose determination study for CDX-1140 in November. The drug is supposed to activate immune responses to cancer, but it looks like Celldex didn't even measure tumors to see if they responded.

CDX-301 helped 5 out of the first 9 advanced-stage lung cancer patients treated in a phase 2 study survive for four months without any signs of disease progression. The candidate was combined with radiation treatment in a single-arm study, so we can't be sure the radiation didn't do all the work.

Now what

The good news for Celldex is that there are still a lot of deep-pocketed pharmaceutical companies eager to pump up their pipelines with oncology assets.

Celldex finished the third quarter with $105.6 million in cash and securities after losing just $7.2 million during the three-month period. That could give the company's early-stage candidates plenty of time to shine before the company needs to ask investors for more capital.

10 stocks we like better than Celldex Therapeutics

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Celldex Therapeutics wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 14, 2018

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Celldex Therapeutics and Nasdaq. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CLDX

Other Topics

Stocks

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More